{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=88",
    "query": {
      "intervention": "Injectable saline",
      "page": 88
    },
    "page_size": 10
  },
  "pagination": {
    "page": 88,
    "page_size": 10,
    "total_count": 2103,
    "total_pages": 211,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=89&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=87&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T13:27:47.280Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02807181",
      "title": "SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Intrahepatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin-gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sirtex Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2017-02-14",
      "completion_date": "2021-04-29",
      "has_results": true,
      "last_update_posted_date": "2025-05-09",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 1,
      "location_summary": "Spokane, Washington",
      "locations": [
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807181"
    },
    {
      "nct_id": "NCT01525901",
      "title": "Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "22q13 Deletion Syndrome",
        "Phelan-McDermid Syndrome"
      ],
      "interventions": [
        {
          "name": "Insulin-Like Growth Factor-1 (IGF-1)",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "5 Years to 12 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-02",
      "completion_date": "2016-08-23",
      "has_results": true,
      "last_update_posted_date": "2022-05-12",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525901"
    },
    {
      "nct_id": "NCT02764801",
      "title": "Contrast-enhanced Ultrasound Evaluation of Chemoembolization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Chemoembolization, Therapeutic"
      ],
      "interventions": [
        {
          "name": "Ultrasound contrast agent (Contrast-enhanced ultrasound)",
          "type": "DRUG"
        },
        {
          "name": "Logiq E9 Scanner (Contrast-enhanced ultrasound)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2016-04",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02764801"
    },
    {
      "nct_id": "NCT04173819",
      "title": "Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "3BNC117-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 225,
      "start_date": "2020-02-18",
      "completion_date": "2023-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173819"
    },
    {
      "nct_id": "NCT05123222",
      "title": "Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Zika Virus"
      ],
      "interventions": [
        {
          "name": "ZIKV-SJRP/2016-184 Strain",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: ZIKV-Nicaragua/2016 Strain",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-02-16",
      "completion_date": "2024-09-03",
      "has_results": true,
      "last_update_posted_date": "2025-04-11",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123222"
    },
    {
      "nct_id": "NCT06265272",
      "title": "Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Liver Cirrhosis",
        "Hepatic Cell Carcinoma",
        "Portal Hypertension"
      ],
      "interventions": [
        {
          "name": "Injection of a gadolinium contrast agen",
          "type": "DRUG"
        },
        {
          "name": "Radiotracer Injection",
          "type": "DRUG"
        },
        {
          "name": "Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 45,
      "start_date": "2023-12-10",
      "completion_date": "2028-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 1,
      "location_summary": "Charlestown, Massachusetts",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265272"
    },
    {
      "nct_id": "NCT01495962",
      "title": "The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wound; Abdomen, Abdominal Wall"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin Type A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2011-11",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-04-27",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495962"
    },
    {
      "nct_id": "NCT04722003",
      "title": "Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gonorrhoea"
      ],
      "interventions": [
        {
          "name": "Meningococcal Group B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 52,
      "start_date": "2021-11-01",
      "completion_date": "2023-10-02",
      "has_results": true,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04722003"
    },
    {
      "nct_id": "NCT04606602",
      "title": "Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperlipidemias",
        "Dyslipidemias",
        "Elevated Lp(a)"
      ],
      "interventions": [
        {
          "name": "SLN360",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Silence Therapeutics plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-11-18",
      "completion_date": "2023-08-23",
      "has_results": false,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04606602"
    },
    {
      "nct_id": "NCT03848845",
      "title": "Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "belantamab mafodotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-03-14",
      "completion_date": "2023-06-14",
      "has_results": true,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-11-09T13:27:47.280Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03848845"
    }
  ]
}